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Background: Hepatitis E virus (HEV) is the leading cause of acute hepatitis
throughout the world. Increasing blood component transfusion-associated
HEV infections highlight the need for reliable virus inactivation procedures for
plasma derivatives from pooled plasma donations.
Study Design and Methods: An animal infection study was conducted to
evaluate the efficiency of HEV inactivation by pasteurization during the
manufacturing process of the von Willebrand Factor/Factor VIII (VWF/FVIII)
concentrate Haemate P/Humate-P (CSL Behring, Marburg, Germany). For this
purpose, groups of pigs were inoculated with stabilized VWF/FVIII intermedi-
ate spiked with HEV-positive liver homogenate and exposed to increasing
incubation times of 0, 3, 6, and 10 h at 60°C. Animals were evaluated for virus
replication over 27 days and in a subsequent trial over 92 days.
Results: Virus replication was detected in animals up to the 6-h pasteurization
group. In contrast, pasteurization for 10 h did not reveal virus detection when
the observation period was 27 days. In an additional experiment using the
10-h pasteurized material, two individuals started virus excretion and
seroconverted when the observation period was extended to 92 days. Based on
the total infection rate (2 of 12) of the animals inoculated with the sample pas-
teurized for 10 h, a virus reduction factor of at least 4.7 log10 is calculated.
Conclusion: This study demonstrates that pasteurization at 60°C for 10 h of an
HEV-positive plasma derivative leads to the effective reduction of infectivity,
resulting in a VWF/FVIII product with an appropriate margin of safety for HEV.
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1 | INTRODUCTION
So far, four genotypes of the Hepatitis E virus (HEV),
assigned to the genus Orthohepevirus, species
Orthohepevirus A,1 have been found to be human patho-
genic. The most prevalent HEV genotype in developed
countries is HEV genotype 3 (HEV-3), which is zoonotic
and is responsible for sporadic HEV cases in humans.
The infection mainly occurs through food-borne trans-
mission routes. The main reservoirs are pigs and wild
boar. Numerous studies revealed the ubiquitous presence
of HEV-3 in these animals.2–4 Human infections with
HEV can range from subclinical mild to more severe clin-
ical courses with jaundice and fulminant liver failure.5
Extrahepatic manifestations and chronic courses in immu-
nocompromised patients have been reported.6–9 A possible
source of transmission in these cases was contaminated
blood products that came from viremic blood donors.10
The risk of infection should not be neglected as HEV-
positive blood donations (based on serology or nucleic acid
amplification techniques) were detectable with up to
0.08%11 to 0.12%12 in Germany, 0.035% in the United
Kingdom,13 0.04% in Denmark,14 0.045% in France,15
0.14% in The Netherlands,16 and 0.002% in the United
States.17 HEV transmission through various blood compo-
nents like fresh frozen plasma (FFP; including amatosalen-
treated FFP), red blood cell concentrates, and platelet con-
centrates, as well as solvent/detergent (SD) plasma, has
been reported.18,19 Therefore, the European Pharmaco-
poeia requires screening of pooled SD plasma for a mini-
mal amount of HEV RNA (≤ 2.5 log10 IU/ml).18
This underlines the need for reliable virus inactiva-
tion/removal procedures to ensure the safety of plasma-
derived products as the starting material of these prod-
ucts are pools of plasma with up to several thousand
donations. The incidence rate in the donor population
(HEV RNA reactive donations) differs between geo-
graphic regions; the rate varies between approximately
1 in 700, 1 in 4500, 1 in 7000, and 1 in 8000 for some
European countries and 1 in 43 000 donations for the
United States.17,20–22
Up to now, there has been only little information about
the impact of chemical and/or physical treatments on the
stability of HEV due to limitations of cell culture models.
Only specific clones from cell lines and only specific HEV
isolates—typically with additional insertions—can be used
as the starting material for cell culture-derived HEV
replication.23–25 Depending on the virus strain used,
approximately 27 000 and 1000 HEV RNA copies, respec-
tively, are required for one cell culture infectious dose,
demonstrating the low sensitivity of a cell culture for HEV
infection.23,25 Thermal stability of HEV has been analyzed
in a few in vitro studies primarily covering food
contaminated with HEV; the inactivation capacity varies
depending on genotypes, used temperature, and duration
of heat exposure,26–32 but the parameters are not related to
the pasteurization of plasma-derived products. This high-
lights the need for alternative and sustainable models to
monitor HEV infectivity and to validate inactivation
methods for these medicinal products.
A plasma-derived product (von Willebrand Factor/
Factor VIII [VWF/FVIII] concentrate [Haemate
P/Humate-P; CSL Behring, Marburg, Germany]), puri-
fied, stabilized by sucrose/glycine to prevent protein
denaturation during pasteurization (heat treatment in
stabilized aqueous solution at 60°C for 10 h), and finally
lyophilized, was employed in this study. The stabilized
VWF/FVIII intermediate was mixed with liver homoge-
nate from an HEV-infected pig and pasteurized for 3, 6,
and 10 h at 60°C and subsequently inoculated to pigs
according to an established pig infection model.33 Pigs
were analyzed for fecal virus shedding, viremia, antibody
production, and virus distribution in tissues to determine
the potential reduction of infectivity by pasteurization.
As HEV is a quasienveloped virus, the relevance of the
HEV spiking material derived from pig liver was compared
to HEV from human plasma and pig feces. This membrane-
associated quasi-enveloped virus is released from cells into
the bloodstream via the host cell ESCRT mechanism and is
mediated by HEV open reading frame 3 (ORF3) protein,
which binds to proteins of the endosomal sorting complex
required for transport (ESCRT) pathway. The virus capsids
are covered by lipid membranes that resemble the lipid
membranes of exosomes, which is removed after entering
the bile and is subsequently shed in the feces as nonen-
veloped virion.34,35
2 | MATERIAL AND METHODS
2.1 | Preparation of inoculum
The inoculum used consists of a sucrose-/glycine-stabilized
VWF/FVIII (Haemate P/Humate-P) intermediate spiked
with the liver homogenate of an experimentally HEV-
infected wild boar from a previous study.33 The liver mate-
rial was minced, ground, and dissolved in phosphate-
buffered saline (PBS) to obtain a 20% liver homogenate,
which was subsequently sterile filtered using a 0.22-μm
MILLEX-GP Syringe Filter Unit (Millipore, Ireland). An
aliquot was set aside to function as native control and
stored at −80°C. The remaining homogenate was thor-
oughly mixed at a ratio of 1:11, with the VWF/FVIII inter-
mediate stabilized to 110% stabilizer concentration to
achieve a stabilizer concentration equivalent to production
conditions (100% stabilizer concentration). The mixture
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was divided into four aliquots. Besides one untreated con-
trol (0 h control), stored at 80°C after preparation, the
additional aliquots were pasteurized at 60.0°C ± 0.5°C in a
calibrated water bath for 3, 6, and 10 h. After reaching
60 ± 0.5°C (warm-up period of 25 min), the timer was
started. The temperatures of the water bath and of a mock
spiked sample in this water bath were monitored with a
calibrated thermometer during the pasteurization experi-
ment. Aliquots were taken at 3, 6, and 10 h after heat
treatment; were cooled on ice; and were stored at −80°C
after generation; all pasteurized samples, as well as the
untreated control (0 h control), were stored at −80°C until
inoculation in pigs was performed (Table 1).
2.2 | Equilibrium centrifugation in a
sucrose density gradient
HEV particles from different sources were tested for the
presence of a quasienvelope. HEV-3-positive serum and
feces samples, as well as liver homogenate, were derived
from individual pigs, originating from existing animal
experiments (LALLF M-V/TSD/7221.3-2.1-017/13). Human
samples were derived from a plasma donation of a donor
infected with HEV (CSL Behring). An equilibrium centrifu-
gation of plasma, liver, and feces material by sucrose gradi-
ent was carried out according to a previously published
study.36 Samples were left native or incubated with 2% NP-
40 at 37°C for 1 h prior to ultracentrifugation. NP-40
(Sigma-Aldrich) is a nonionic detergent that solubilizes
plasma membrane. In short, 13.2-ml Ultra-Clear tubes
(Beckman&Coulter, Krefeld, Germany) were filled with a
sucrose density gradient with increasing concentrations of
sucrose (60%, 40%, 30%, and 20% sucrose; 10% sucrose in
Tris-NaCl-EDTA (TNE) buffer (50 mM Tris HCl, 150 mM
NaCl, 1 mM Ethylenediaminetetraacetic acid) followed by
3 ml TNE buffer). Centrifugation was performed in an SW-
41TI rotor (Beckman&Coulter) in an L7-55 ultracentrifuge
(Beckman&Coulter) at 21,0000 g at 4°C for 4 h. Overall,
18 fractions were recovered, starting from the top with
seven 1-ml fractions followed by eleven 500-μl fractions,
and analyzed via HEV-specific quantitative real time
reverse transcription polymerase chain reaction (qRT-
PCR). Sucrose concentration in fractions was monitored
using a Refractometer (Brix scale).
2.3 | Experimental design of the animal
study
The competent authority of the Federal State of Mecklen-
burg Western-Pomerania approved all described animal
experiments based on national and European laws
(approval number of the local authorities: LALLF M-V/
TSD/7221.3-2.1-017/13). For this experiment, 46 large white
pigs from a commercial breeder were used. The animals
were maintained under containment conditions in a Bio-
safety Level 3 facility during the study. Prior to acquisition,
all animals were tested for the absence of signs of HEV by
RT-qPCR and ELISA in blood and feces and were retested
prior to inoculation. Furthermore, all animals were tested
free of porcine reproductive and respiratory syndrome virus
and porcine circovirus 2, as well as for African swine fever
virus, foot-and-mouth-disease virus, and suid herpesvirus
1, employing a quantitative multiplex RT-PCR37 The inves-
tigation was performed twice at the stable of origin, as well
as at the facilities of Friedrich-Loeffler-Institut (FLI). The
animals were randomly divided into groups (Table 1).
Untreated horizontal controls were housed with the inocu-
lated animals except in group r0 h (second set of experi-
ment). Sentinel (control) animals were used to demonstrate
the productive HEV infectivity of the inoculated animals
through fecal–oral transmission38,39 After stabling, the ani-
mals were divided into the corresponding groups and held
in quarantine for 2 weeks in separate stable units. Complete
change of protective clothes, as well as wearing of filtering
face piece 3 (FFP3) masks, was mandatory before entry into
each of the rooms. Daily animal manipulation always
began in the 10-h pasteurization group, followed by the 6-,
3-, and 0-h pasteurization groups.
The inoculation was performed with a 2-ml dose of
inoculum intravenously into the vena cava cranialis.
Animal behavior and rectal body temperature were
checked daily. As described in previous studies, body
temperatures over 40°C for at least two consecutive
days were considered a febrile response.33,40 Depres-
sion, diarrhea, vomitus, icterus, ascites, and neurologi-
cal symptoms were considered signs of acute hepatitis
and would have led to immediate removal and euthana-
sia of the animal.
During the experiments, blood and fecal samples
were taken regularly every 2–3 days. The corresponding
serum samples were stored at −20°C. From the fecal sam-
ples, a 10% fecal suspension was made using 0.89% NaCl
solution. After vortexing and centrifugation (4400 g, 4°C,
20 min), the supernatant was sterile filtered using a
0.22-μm MILLEX-GP Syringe Filter Unit (Millipore, Ire-
land) and stored at −20°C. To further evaluate the distri-
bution of HEV in the inoculated animals, at the end of
each an experimental setup, the animals were euthanized
(electro stunning followed by exsanguination). Necrop-
sies were performed, and samples from blood, feces, bile,
and different tissues were aliquoted for RNA extraction
and stored at −20°C. Tissue samples were treated with
4% neutral buffered formalin for further histological and
immunohistochemical studies (see Supplement).
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2.4 | RNA and antibody detection
RNA extraction of serum, fecal filtrate, and bile was per-
formed manually using the QIAmp Viral Mini Kit (Qiagen)
following manufacturer's instruction. Manual RNA extrac-
tion from tissue samples was performed with the RNEasy
Mini Kits (QIAGEN GmbH, Hilden Germany). A heterolo-
gous internal control was added to each extraction sample.
Obtained RNA was stored at −80°C until further use. To
monitor the course of the infection and to quantify viral
shedding and viremia, quantitative real-time RT-PCR
(qRT-PCR) with standard curves was performed as
described previously.41 The immunological response was
monitored using the Priocheck HEV Ab porcine enzyme-
linked immunoassay (ELISA) (Mikrogen GmbH, Neuried,
Germany), a porcine-specific anti-HEV IgG ELISA; the cut-
off was calculated as mean OD450 of the cut-off control
(component of the test kit) multiplied by 1.2 according to
manufacturer's instructions.
2.5 | Statistical evaluation of the
correlation of pasteurization time and time
to detection of HEV infectivity
To assess a correlation between the pasteurization time
(in hours) and the length of time (in days) of the first detec-
tion of HEV replication within the pigs of one group,
Pearson's correlation was applied (calculated using SYS-
TAT); no linear relationship of the two continuous vari-
ables exists at Pearson's correlation coefficient of near
0, and a strong linear relationship exists at ±0.8 or higher.
2.6 | Calculation of virus titers and virus
reduction factor
As published previously in an accompanying study, the
liver tissue used for spiking had an infectivity titer of 5.8
log10ID50/ml calculated according to Spearman–Kärber as
outlined in additional file 3 of a previous publication.44 As
20% liver homogenate was used for spiking, a 1:5 dilution
and a further 1:11 dilution by spiking with VWF/FVIII
intermediate has to be considered for the titer of the inocu-
lum. The logarithmic titer of the spiked untreated sample
(0 h, Group B) was, thus, calculated as follows:
5:8 log10 ID50 + log10 1 : 5ð Þ+ log10 1 : 11ð Þ=5:8 log10
−0:7 log10−1:0 log10 = 4:1 log10 ID50=ml
The virus reduction factor is calculated according to
the relevant European guideline, Appendix II,42 taking
into consideration the virus load in the starting material
divided by the virus load in the final sample of
manufacturing step. As the volume of the product inter-
mediate does not change during pasteurization, for the
calculation of the virus reduction factor, the virus load is
equivalent to the virus titer. Thus, the virus reduction fac-
tor (inactivation factor) is calculated as the difference of
the logarithmic factor of the spiked starting material and
of the final sample (10 h pasteurization time).
The infectious titer of the 10-h pasteurized HEV-spiked
product intermediate was calculated according to Spearman–
Kärber based on the reactivity rate of animals positive for
HEV RNA in feces during the first 27 days after inoculation.
Rules for titer calculation were the same as described in the
study for the determination of the liver tissue.43 The virus
reduction factor (VRF) by pasteurization was calculated
based on logarithmic titers of the 0-h and the 10-h samples:
log10 titer (0 h) - log10 titer (10 h) = VRF [log10].
3 | RESULTS
3.1 | Density and composition of HEV
virions from human plasma, porcine liver,
and feces
To analyze HEV virions derived from human plasma and
porcine liver, corresponding samples were applied to
equilibrium centrifugation in a sucrose gradient (10%-
60% w/v) and subsequently tested for HEV-derived RNA
via PCR (Figure 1). In human plasma, most of HEV-
derived RNA was found in an interval of sucrose concen-
trations of 15%–40%, with the highest concentrations
between 22% and 32% sucrose (Figure 1(A)). The bulk of
HEV in liver material was found in the range of 21%–43%
sucrose, with the highest HEV RNA concentrations
between 27% and 43% sucrose (Figure 1(B)). In contrast,
HEV-derived RNA from feces peaked at 37%–47%
sucrose, indicating a different density of feces-derived
virions (Figure 1(C)). Application of detergent NP-40 led
to a change in density regarding plasma and liver-derived
particles to 44%–47% sucrose. However, particles from
feces only slightly changed density, indicating the lack of
a quasienvelope in feces material (Figure 1(A)–(C)).
3.2 | HEV RNA concentration in inocula
Inocula were prepared according to the Material and
Methods section and have undergone subsequent heat
inactivation treatment for increasing pasteurization times
at 60°C. The HEV copy numbers in the liver homogenate
had an HEV load of 3.9*103 RNA copies/μl, and the
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intermediate spike of 1:11 had an approximately 10-fold
lower HEV RNA concentration; the HEV RNA concentra-
tion did not decrease considerably by pasteurization. A
general summary including individual pig designation and
the observation/incubation period is shown in Table 1.
3.3 | Clinical parameters and pathology
None of the animals showed a febrile response or any
clinical signs consistent with hepatitis throughout the
whole experiment. Animal P3-20 showed signs of
regurgitation resulting in poor growth but could other-
wise be considered clinically inconspicuous. No signs of
viral hepatitis could be detected on gross examination at
necropsy (data not shown).
3.4 | Virus detection in feces and serum
Feces and serum of inoculated pigs were tested regularly
via HEV-specific qRT-PCRs to investigate productive
virus replication. Starting from the control group (native
liver homogenate) up to the 6-h pasteurization group, all
inoculated animals displayed virus shedding within the
observation period albeit at different time points. The Pear-
son correlation showed a high association between the
parameter pasteurization time (0, 3, 6, and 10 h) and time
FIGURE 1 Sucrose density gradient fractionation of Hepatitis E virus genotype 3-positive human plasma (A), pig liver homogenate (B),
and pig feces (C) with (blue line) or without (red line) prior treatment with NP-40 [Color figure can be viewed at wileyonlinelibrary.com]
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to detection of HEV replication in the inoculated pigs dem-
onstrated by HEV RNA positivity in feces and by serocon-
version. HEV antibodies in the serum of inoculated pigs
are detected, on average, 7 days (range 0–17 days) after
HEV shedding is demonstrated in feces. Delayed virus
detectability related to increased pasteurization times
implies an inactivation of HEV (Table 2).
In groups of pigs where HEV shedding in feces was
observed, the sentinel (contact) animals also started shed-
ding HEV (except for the sentinel animal in the “0h pas-
teurization time” group) but with a delayed onset of at least
10 days (Figure 2), indicating a fecal–oral transmission.
In the control group (diluted liver homogenate,
untreated, Figure 2(A)), all inoculated animals started
shedding viral RNA in their feces within 3–6 days post
infection (dpi). A fecal–oral transmission occurred as HEV
RNA was observed at 13 dpi in the feces of the contact ani-
mals. Animals inoculated with spiked product intermediate
not pasteurized (0 h) and pasteurized for 3, 6, and 10 h
(Figure 2(B)–(F))) started shedding viral RNA in their feces
within 6–15 dpi, 9–13 dpi, 13–15 dpi, and 27–30 dpi,
respectively. In the 10-h pasteurization groups, six and
three animals did not show any signs of HEV infection
(incubation period up to 27 days and 92 days, respectively),
and in the third group of three animals, two showed HEV
replication due to inoculation of the spiked treated mate-
rial. As the infection of the contact animal was observed by
HEV shedding in the feces starting on day 45, the third
inoculated animal with virus shedding from day 55 dpi
onward is considered to have been secondarily infected.
Details on HEV detection in tissues and body fluids
(bile, liver, gall bladder, lymph nodes, spleen, and pan-
creas) for each animal in the study after necropsy are
compiled in Supplement (Table S1).
3.5 | Infectivity titers of pasteurized
samples and HEV reduction factor for the
pasteurization of VWF/FVIII
Test results of animals for HEV RNA in feces during the
incubation time of 27 days are documented in Figure 2.
As for the spiked samples after 0, 3, and 6 h of heat
treatment only, 2-ml aliquots of the undiluted samples
were tested in groups with nine, six, and six inoculated
animals, and as all animals of the respective groups
became reactive for HEV RNA in feces within the 27-day
observation period, no infectivity titer could be calculated
based on Spearman–Kärber. Nevertheless, for the 0-h
sample, a theoretical titer of 4.1 log10 ID50/ml could be
calculated using the infectivity titer of the liver homoge-
nate used for spiking, known from a published accompa-
nying study (see Material and Methods). On the other
hand, in groups E and F inoculated with 2-ml aliquots of
the sample after 10-h pasteurization, zero and 2 of six
animals became reactive for HEV RNA within the 27-day
observation period. Thus, a Spearman–Kärber titer could
be calculated based on the additional conservative
assumption that a 10-fold concentrated sample would
have led to a reactivity rate of 1. Consequently, the titer
of the 10-h sample was calculated to be ≤−0.6
log10ID50/ml. According to the European guideline
[CPMP/BWP/268/95],42 the titer of the final sample (≤−0.6
log10, 10-h sample) has to be subtracted from the titer of
the starting material (4.1 log10, 0 h sample), resulting in a
VRF of ≥4.7 log10 for the pasteurization of VWF/FVIII.
4 | DISCUSSION
In the last few years, transfusion-associated HEV
infections from HEV-positive blood donations raise ques-
tions about plasma product safety against HEV as HEV
can be detected in plasma donations, as well as in plasma
pools for fractionation.22,44–47 The virus load in plasma
pools for fractionation is low, never exceeding 1000
copies/ml.47 Heat treatment has only a minor impact on
the titer of virus nucleic acids48—this fact is also observed
in our current study. Therefore, the absence of detectable
HEV RNA in the final preparations of plasma-derived
coagulation factors49 may be attributed mainly to the
capacity of protein purification steps and virus filtration
steps in some manufacturing processes50 to reduce the
HEV particle load. Consequently, the destruction of HEV
infectivity by heat treatment adds a safety margin on top
of a nondetectable HEV RNA load.
TABLE 2 Correlation of pasteurization time and first detection of hepatitis E virus (HEV) replication in pigs
First time of HEV detected in an animal of each category [dpi]
Sample studied Pasteurization time Pearson's correlation coefficient
0 h (group B) 3 h (group C) 6 h (group D) 10 ha (group E-F)
Feces (HEV PCR) 6 9 13 27 0.959
ELISA (HEV antibodies) 17 21 27 27 0.932
aProlonged observation period (92 days).
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FIGURE 2 Results of the RT-qPCR from feces and serum and the results of Priocheck ELISA from serum of all inoculated animals from
the control (A) and the 0-h (B), 3-h (C), 6-h (D), 10-h (E), and the elongated 10-h (F) groups. The figures display the time course (days after
inoculation) of all individuals, indicating copy number and corresponding optical density. The color code green represents not detected,
yellow for borderline, and red for detection [Color figure can be viewed at wileyonlinelibrary.com]
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The considerable heat resistance of HEV is known
from preparing food: incubation of liver material at 56°
for 1 h induced an HEV infection in four of five animals,
26 and heating at 62°C for 120 min resulted in the infec-
tion of three of four pigs, whereas exposure to 71°C for
20 min completely inactivated HEV.27 Using a cell
culture infectivity study, cell culture supernatant treated
at 60°C caused complete inactivation of the virus after
10 min.32
A widely used method for virus inactivation in
plasma-derived medicinal products is pasteurization at
60°C for 10 h; CSL Behring's pasteurization step is per-
formed in intermediates stabilized commonly by high
sucrose concentration, together with glycine or potassium
acetate, to protect the plasma proteins from heat denatur-
ation.51 The efficacy for this thermal treatment has been
demonstrated previously for a large variety of viruses,
including human immunodeficiency virus, bovine viral
diarrhea virus as a model virus for hepatitis C virus and
West Nile virus, herpesviruses, Hepatitis A virus, parvovi-
rus B19, and others.51 Such pasteurization studies were
previously not performed for HEV except for human
serum albumin (HSA), which is not stabilized by sucrose
and glycine or potassium acetate50,52 but only by cap-
rylate and N-acetyltryptophan, and these components do
not affect the inactivation kinetics of a range of viruses.
HEV inactivation data in HSA are not consistent. In
12.5% HSA, HEV was inactivated at 58 ± 1°C below the
limit of detection of a cell culture infectivity assay within
180 min, resulting in a virus reduction factor of more
than 3.1 log10.
50 In a different study in 25% HSA, different
strains of HEV genotypes 3 and 4 showed considerable
heat resistance with inactivation factors between 1.0 and
≥2.2 log10 within 5 h at 60°C52; in contrast to these data
in HSA, the authors demonstrated a rapid HEV inactiva-
tion in PBS, resulting in reduction factors of ≥2.4 to ≥3.7
log10 within 30 min at 60°C. This is in line with published
data32 demonstrating that cell culture-derived virus
stocks were already inactivated within 60 min below the
limit of detection. As the current data from the pasteuri-
zation of HEV in HSA vary, and some viruses remain
very stable when pasteurized in the presence of
sucrose,51 the VRF of 4.7 log10 observed in this study is
surprisingly high as HEV was also treated in a sucrose-
stabilized solution. Pasteurization is therefore an effective
step in reducing HEV infectivity under the conditions
used in the current study. As the stabilizer composition
used during the pasteurization of plasma-derived prod-
ucts (to protect the heat-sensitive plasma proteins from
denaturation) has an effect on the heat inactivation
capacity of this manufacturing step for certain viruses,51
it is advisable to assess the HEV inactivation capacity of
other pasteurization processes in product-specific virus
validation studies wherever stabilizer composition is con-
siderably different from the composition in the
VWF/FVIII intermediate.
Commonly, samples from the validation of virus
inactivation procedures are assessed in cell culture sys-
tems to quantify the reduction of virus titer. Despite the
fact that some HEV studies are performed employing
cell culture systems, currently, a suitable and sensitive
cell culture system is not available; published data show
that one cell culture infectious unit corresponds to at
least approximately 1000 HEV RNA copies,23,52 whereas
the minimum infectious dose for pigs corresponds to 6.5
copies (equivalent to 24 IU HEV RNA/ml).44 Therefore,
pig infection experiments are the sole possibility to
determine potential HEV inactivation and remaining
virus infectivity with a high sensitivity, dynamic range,
and relevance for human patients, especially because
pigs exhibit many similarities with humans in anatomy,
physiology, and immunology.53 We, therefore, used this
species to evaluate the impact of increasing pasteuriza-
tion times on stabilized VWF/FVIII (Haemate
P/Humate-P) intermediate spiked with HEV-positive
liver homogenate.
As recent studies suggested that HEV particles from
cell culture supernatant36,54,55 and human serum56 are
quasienveloped by a lipid layer in contrast to nonen-
veloped HEV57 derived from feces, in an initial in vitro
approach, the density of HEV particles from different
sources was analyzed and compared with HEV parti-
cles from human plasma to select the most appropriate
HEV spike material for the study. For this approach,
ultracentrifugation of HEV from porcine liver, porcine
feces, and human plasma was performed in a sucrose
gradient. Our results show that a distinct proportion of
both liver- and plasma-derived HEV particles contains
a lipid layer, which was demonstrated by a shift in par-
ticle density after treatment with the detergent NP-40.
No corresponding shift was observed in feces-derived
HEV material as bile acts, to some extent, as a surfac-
tant, removing the lipid from the HEV particles. The
lipid layer seems to interfere with infectivity as feces-
derived HEV exhibits a higher infectivity in humanized
mice compared to other sources.58 Therefore, the intra-
venous application of liver-derived HEV material in
our experimental pig trial best mimics the transmission
routes and sources of blood-transmitted HEV.
In general, increasing pasteurization times caused a
significant increase in time until virus shedding in feces
and in the detection of anti-HEV (up to total absence).
Infections of the animals by original injection cannot
clearly be discriminated from subsequent oral infections
(documented for contact animals) when animals are
grouped in one stable. Therefore, a secondary (oral)
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infection of inoculated but not infected animals was
defined when the time gaps of onset of virus shedding
were 10 days or more between individuals of one cohort.
Based on this definition, the virus-spiked inoculum pas-
teurized for 10 h infected 2 of 12 inoculated pigs, and in
all other groups, all inoculated animals are considered to
be infected by the inoculum.
For the welfare of animals, that is, to minimize the
number of animals used in the study, no hold control was
included where spiked starting material is maintained at
room temperature for 10 h. This was regarded as accept-
able because the VWF/FVIII intermediate at this stage
contains no immunoglobulins. This was known from
analytical data and pasteurization studies with Hepatitis
A virus (HAV) and parvovirus B19 (B19V), where the
respective hold controls showed no titer decrease when
compared to the spiked starting material directly after
spiking, indicating the absence of neutralizing antibodies
to these viruses (unpublished data). Therefore, the likeli-
hood that losses in infectivity in the HEV pasteurization
study could be attributed to neutralization or interference
rather than to the heat treatment is low.
In conclusion, we could demonstrate effective inactiva-
tion of HEV by pasteurization of the VWF/FVIII interme-
diate in an aqueous, stabilized solution spiked with HEV-
positive liver material, with a quasienvelope comparable to
that of a plasma-derived HEV and applied intravenously.
An assessment regarding the risk for HEV transmis-
sion for the VWF/FVIII product Haemate P/Humate P is
performed.59 This risk assessment takes into account the
HEV load in the starting material plasma pool for frac-
tionation (not exceeding 1000 IU/ml47), the volume of
plasma required to produce one vial of product (consider-
ably less than 10 L), the virus reduction capacity of the
manufacturing process (pasteurization), and further
manufacturing steps contributing to the overall virus
reduction capacity as demonstrated for a wide range of
enveloped and nonenveloped viruses,60 and the mini-
mum amount of HEV required to infect a patient (4.4
log10 IU)
61 ensures an appropriate margin of safety
regarding potential HEV transmission.
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